Nymox Pharmaceutical Corporation announced that a newly completed clinical study has shown that the Company's AlzheimAlert urine test has new clinical utility in the assessment of patients with symptoms of dementia. The study found in cases with confirmed cerebral vascular abnormalities associated with the mental symptoms, that the AlzheimAlert test values were significantly lower than in cases of Alzheimer's Disease (AD).

This represents an entirely new use of the neural thread protein (NTP) AlzheimAlert urine test, according to the Company. The new study found that 18 out of 20 consecutive examples of blinded coded confirmed vascular cases had AlzheimAlert values out of the range of AD cases. These findings reached statistical significance, a company release says.

In the new study, individuals from several independent US institutions provided blinded coded urine samples which were tested in Nymox's CLIA certified Clinical Reference Laboratory in Maywood, New Jersey. The subjects were evaluated and were given CT and MRI scans, which were read by different specialists in the individual institutions. Although the cases with vascular abnormalities were symptomatic and had cognitive deficits, their urine tests (in 90%) remained within the normal range. Cases of AD (over 90%) had elevated NTP values.

The results of the new study will be published in a peer-reviewed medical journal, the company release said.